Fox E, et al. Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS). ECTRIMS 2018, abstract 229.
ZonMw investeert in verbeteren leefstijl na beroerte
jan 2024 | Myocardinfarct, Neuro-vasculair